State Street’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-1,732,506
| Closed | -$41.8M | – | 4816 |
|
|
2023
Q1 | $41.8M | Buy |
1,732,506
+174,268
| +11% | +$2.19M | ﹤0.01% | 1776 |
|
|
2022
Q4 | $16.5M | Buy |
1,558,238
+263,813
| +20% | +$2.13M | ﹤0.01% | 2386 |
|
|
2022
Q3 | $5.82M | Buy |
1,294,425
+85,236
| +7% | +$388K | ﹤0.01% | 2989 |
|
|
2022
Q2 | $4.84M | Sell |
1,209,189
-65,477
| -5% | -$310K | ﹤0.01% | 3120 |
|
|
2022
Q1 | $9.33M | Buy |
1,274,666
+61,956
| +5% | +$371K | ﹤0.01% | 2866 |
|
|
2021
Q4 | $6.82M | Sell |
1,212,710
-213,028
| -15% | -$1.35M | ﹤0.01% | 3103 |
|
|
2021
Q3 | $9.12M | Buy |
1,425,738
+97,401
| +7% | +$626K | ﹤0.01% | 2934 |
|
|
2021
Q2 | $11.2M | Buy |
1,328,337
+242,728
| +22% | +$1.96M | ﹤0.01% | 2857 |
|
|
2021
Q1 | $11.4M | Buy |
1,085,609
+89,644
| +9% | +$1.26M | ﹤0.01% | 2676 |
|
|
2020
Q4 | $16.9M | Sell |
995,965
-37,274
| -4% | -$559K | ﹤0.01% | 2340 |
|
|
2020
Q3 | $13.3M | Buy |
1,033,239
+167,640
| +19% | +$2.12M | ﹤0.01% | 2279 |
|
|
2020
Q2 | $12.2M | Buy |
865,599
+846,499
| +4,432% | +$10.7M | ﹤0.01% | 2313 |
|
|
2020
Q1 | $176K | Sell |
19,100
-3,630
| -16% | -$46.8K | ﹤0.01% | 3581 |
|
|
2019
Q4 | $339K | Buy |
22,730
+5,630
| +33% | +$50.2K | ﹤0.01% | 3571 |
|
|
2019
Q3 | $117K | Buy |
+17,100
| New | +$173K | ﹤0.01% | 3658 |
|
Other funds holding PRVB
State Street's PRVB Position: Q2 2023 in Review
State Street sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,732,506 shares — an estimated $41.8M sold.
State Street first reported a position in PRVB in Q3 2019 and held it in 15 quarters. The position peaked at $41.8M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- State Street reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- State Street sold 1,732,506 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $41.8M.
- State Street first reported a position in Provention Bio, Inc. Common Stock in Q3 2019 and held it in 15 quarters.
- State Street's Provention Bio, Inc. Common Stock position peaked at $41.8M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on State Street's 13F filing for Q2 2023, filed 14 Aug 2023.